Evidence map›Paper›PMID 40515959›Full record

ArticleDiscover oncology2025

ZNF432 suppresses endometrial cancer progression by promoting UPF1 ubiquitination and inducing apoptosis.

Xinjun Li, Jie Qi, Ren Xu, Shuo Xu, Shengpu Wang, Chunxiao Wang, Sufen Zhao

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xinjun LiDepartment of Gynecology, The Second Hospital of Hebei Medical University, 215 Heping West Rd., Xinhua District, Shijiazhuang, 050000, Hebei, China.
Jie QiDepartment of Gynecology, Hebei General Hospital, Shijiazhuang, 050000, Hebei, China.
Ren XuDepartment of Gynecology, Hebei General Hospital, Shijiazhuang, 050000, Hebei, China.
Shuo XuDepartment of Gynecology, Hebei General Hospital, Shijiazhuang, 050000, Hebei, China.
Shengpu WangDepartment of Obstetrics, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, China.
Chunxiao WangDepartment of Gynecology, Cangzhou People's Hospital, Cangzhou, 061000, Hebei, China.
Sufen ZhaoDepartment of Gynecology, The Second Hospital of Hebei Medical University, 215 Heping West Rd., Xinhua District, Shijiazhuang, 050000, Hebei, China. 26400626@hebmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial cancer (EC) is a malignant tumor originating from the uterine epithelial lining and is one of the most common gynecologic malignancies worldwide. Ubiquitination, as a crucial regulatory mechanism in cell physiology, plays a key role in processes such as cell cycle control, DNA repair, and tumorigenesis. UPF1, a critical regulator of ubiquitination, is involved in the development of various diseases, including cancer, due to its influence on mRNA stability and protein degradation. This study aims to identify novel molecular targets related to EC pathogenesis and to explore their mechanisms of action. Through bioinformatics analysis, we identified ZNF432 as a significantly differentially expressed gene in EC tissues. Functional experiments demonstrated that ZNF432 overexpression significantly inhibited EC cell proliferation and induced apoptosis. In in vivo experiments, ZNF432 overexpression significantly suppressed tumor growth in a nude mouse xenograft model. Mechanistically, ZNF432 induced apoptosis by interacting with UPF1 and enhancing its ubiquitination, promoting the degradation of pro-survival factors in EC cells. These findings provide new insights into the molecular mechanisms underlying EC and highlight ZNF432 as a potential therapeutic target, offering promising prospects for the development of novel treatments.

Indexed as

ApoptosisEndometrial cancer (EC)UbiquitinationUPF1ZNF432

Identifiers

PMID40515959
PMCPMC12167216

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.